Home > Insider Trading > Filing (0000899243-15-001801)

Filing Details

Accession Number:: 0000899243-15-001801
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2015-07-28 18:32:22
Reporting Period:: 2015-07-24

Filing Date:: 2015-07-28
Accepted Time:: 2015-07-28 18:32:22
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1061027	Sunesis Pharmaceuticals Inc	SNSS	Pharmaceutical Preparations (2834)	943295878

Insiders

Cik	Name	Reported Address	Director	Officer	Large Shareholder	Other
1288452	Bay City Capital Llc	750 Battery Street, Suite 400 San Francisco CA 94111	No	No	Yes	No
1401826	Bay City Capital Fund V, L.p.	750 Battery Street, Suite 400 San Francisco CA 94111	No	No	Yes	No
1409813	Bay City Capital Fund V Co-Investment Fund, L.p.	750 Battery Street, Suite 400 San Francisco CA 94111	No	No	Yes	No
1461543	Bay City Capital Management V Llc	750 Battery Street, Suite 400 San Francisco CA 94111	No	No	Yes	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2015-07-24	1,089,788	$1.32	5,683,475	No	4	X	Indirect	See Footnotes
Common Stock	Disposition	2015-07-24	415,877	$3.46	5,267,598	No	4	S	Indirect	See Footnotes
Common Stock	Acquisiton	2015-07-24	544,893	$1.32	5,812,491	No	4	X	Indirect	See Footnotes
Common Stock	Disposition	2015-07-24	207,938	$3.46	5,604,553	No	4	S	Indirect	See Footnotes
Common Stock	Acquisiton	2015-07-24	20,766	$1.32	5,625,319	No	4	X	Indirect	See Footnotes
Common Stock	Disposition	2015-07-24	7,925	$3.46	5,617,394	No	4	S	Indirect	See Footnotes
Common Stock	Acquisiton	2015-07-24	10,383	$1.32	5,627,777	No	4	X	Indirect	See Footnotes
Common Stock	Disposition	2015-07-24	3,962	$3.46	5,623,815	No	4	S	Indirect	See Footnotes

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	X	Indirect	See Footnotes
No	4	S	Indirect	See Footnotes
No	4	X	Indirect	See Footnotes
No	4	S	Indirect	See Footnotes
No	4	X	Indirect	See Footnotes
No	4	S	Indirect	See Footnotes
No	4	X	Indirect	See Footnotes
No	4	S	Indirect	See Footnotes

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Warrant (right to buy)	Disposition	2015-07-24	1,089,788	$0.00	1,089,788	$1.32
Common Stock	Warrant (right to buy)	Disposition	2015-07-24	544,893	$0.00	544,893	$1.32
Common Stock	Warrant (right to buy)	Disposition	2015-07-24	20,766	$0.00	20,766	$1.32
Common Stock	Warrant (right to buy)	Disposition	2015-07-24	10,383	$0.00	10,383	$1.32

Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
2009-04-03	2016-04-03	No	4	X	Indirect
2009-10-03	2016-10-03	No	4	X	Indirect
2009-04-03	2016-04-03	No	4	X	Indirect
2009-10-03	2016-10-03	No	4	X	Indirect

Footnotes

Bay City Capital LLC, a Delaware limited liability company ("BCC"), Bay City Capital Management V LLC, a Delaware limited liability company ("Management V"), Bay City Capital Fund V, L.P., a Delaware limited partnership ("Fund V"), and Bay City Capital Fund V Co-Investment Fund, L.P., a Delaware limited partnership ("Co-Investment V") are deemed to be a "group" for the purposes of Section 13(d) under the Securities Exchange Act of 1934. Management V is the general partner of Fund V and Co-Investment V and has sole voting and dispositive power with respect to the securities held by Fund V and Co-Investment V. BCC, the manager of Management V, is also an advisor to Fund V and Co-Investment V and has sole voting and dispositive power with respect to the securities held by Fund V and Co-Investment V.
These securities are held by Fund V.
On July 27, 2015, Fund V exercised a warrant to purchase 1,089,788 shares of Sunesis Pharmaceuticals Inc. ("Sunesis") common stock for $1.32 a share. Fund V paid the exercise price on a cashless basis, resulting in Sunesis withholding of 415,877 of the warrant shares to pay the exercise price and issuing to the reporting person the remaining 673,911 shares.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.32 to $3.58 inclusive. Upon request, the reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the Securities and Exchange Commission, full information regarding the shares sold at each separate price within the ranges set forth in footnote four (4) of this Form 4.
On July 27,2015, Fund V exercised a warrant to purchase 544,893 shares of Sunesis common stock for $1.32 a share. Fund V paid the exercise price on a cashless basis, resulting in Sunesis withholding of 207,938 of the warrant shares to pay the exercise price and issuing to the reporting person the remaining 336,955 shares.
These securities are held by Co-Investment V.
On July 27, 2015, Co-Investment V exercised a warrant to purchase 20,766 shares of Sunesis common stock for $1.32 a share. Co-Investment V paid the exercise price on a cashless basis, resulting in Sunesis withholding of 7,925 of the warrant shares to pay the exercise price and issuing to the reporting person the remaining 12,841 shares.
On July 27, 2015, Co-Investment V exercised a warrant to purchase 10,383 shares of Sunesis common stock for $1.32 a share. Co-Investment V paid the exercise price on a cashless basis, resulting in Sunesis withholding of 3,962 of the warrant shares to pay the exercise price and issuing to the reporting person the remaining 6,421 shares.